氨甲环酸在急性创伤性颅脑损伤中的疗效与安全性:随机对照试验的系统评价与荟萃分析
该系统评价与荟萃分析纳入9项随机对照试验、共14,747例年龄≥15岁的急性创伤性颅脑损伤患者,比较氨甲环酸与安慰剂。结果显示,氨甲环酸对死亡率无影响(RR 0.95;95%CI 0.88-1.02;RD降低1.0%;95%CI降低2.5%至升高0.4%;中等确定性),对残疾评定量表评分无显著影响(MD -0.18分;95%CI -0.43至0.08;中等确定性)。氨甲环酸可能减少后续影像学血肿扩大(RR 0.77;95%CI 0.58-1.03;RD 3.6%;95%CI降低6.6%至升高0.5%;低确定性)。不良事件风险在安慰剂组与氨甲环酸组相似(中等、低或极低确定性)。
要点
- 在年龄≥15岁的急性创伤性颅脑损伤患者中,与安慰剂相比,氨甲环酸对死亡率无影响(RR 0.95;95%CI 0.88-1.02;中等确定性)。
- 氨甲环酸对残疾评定量表评分无显著影响(MD -0.18分;95%CI -0.43至0.08;中等确定性)。
- 氨甲环酸可能减少后续影像学血肿扩大(RR 0.77;95%CI 0.58-1.03;RD 3.6%;低确定性)。
- 不良事件风险在安慰剂组与氨甲环酸组相似(中等、低或极低确定性)。
- 该荟萃分析基于9项随机对照试验、共14,747例患者,氨甲环酸可能不增加不良事件风险。
适用人群与场景
- 成人及青少年(年龄≥15岁)急性创伤性颅脑损伤患者。
- 纳入随机对照试验中比较氨甲环酸与安慰剂的患者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:随机对照试验的系统评价与荟萃分析;纳入9项RCT,共14,747例患者;人群为年龄≥15岁的急性创伤性颅脑损伤患者。
- 干预与对照:氨甲环酸 vs 安慰剂。
- 主要终点:死亡率——氨甲环酸对死亡率无影响(RR 0.95;95%CI 0.88-1.02;RD降低1.0%;95%CI降低2.5%至升高0.4%;中等确定性)。
- 残疾评定量表评分——无显著影响(MD -0.18分;95%CI -0.43至0.08;中等确定性)。
- 血肿扩大——氨甲环酸可能减少后续影像学血肿扩大(RR 0.77;95%CI 0.58-1.03;RD 3.6%;95%CI降低6.6%至升高0.5%;低确定性)。
- 不良事件——安慰剂组与氨甲环酸组风险相似(中等、低或极低确定性)。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与荟萃分析。
- 证据分级:采用GRADE方法评估证据质量;死亡率和残疾结局为中等确定性,血肿扩大为低确定性,不良事件为中等、低或极低确定性。
- 局限:原文未述局限性。
对床旁实践的改变
- 在急性创伤性颅脑损伤患者中,氨甲环酸可能对死亡率或残疾无影响,不应仅以改善死亡率或残疾为目的常规使用。
- 氨甲环酸可能减少影像学血肿扩大,但该结局对患者的重要性可能较低。
- 氨甲环酸可能不增加不良事件风险,但需结合具体临床情况评估。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: With the publication of a large randomized-controlled trial (RCT) suggesting that tranexamic acid (TXA) may improve head-injury-related deaths, we aimed to determine the safety and efficacy of TXA in acute traumatic brain injury (TBI).
METHODS: In this systematic review and meta-analysis, we searched MEDLINE, PubMed, EMBASE, CINHAL, ACPJC, Google Scholar, and unpublished sources from inception until June 24, 2020 for randomized-controlled trials comparing TXA and placebo in adults and adolescents (≥ 15 years of age) with acute TBI. We screened studies and extracted summary estimates independently and in duplicate. We assessed the quality of evidence using the grading of recommendations assessment, development, and evaluation approach. This study is registered with PROSPERO (CRD42020164232).
RESULTS: Nine RCTs enrolled 14,747 patients. Compared to placebo, TXA had no effect on mortality (RR 0.95; 95% CI 0.88-1.02; RD 1.0% reduction; 95% CI 2.5% reduction to 0.4% increase, moderate certainty) or disability assessed by the Disability Rating Scale (MD, - 0.18 points; 95% CI - 0.43 to 0.08; moderate certainty). TXA may reduce hematoma expansion on subsequent imaging (RR 0.77; 95% CI 0.58-1.03, RD 3.6%, 95% CI 6.6% reduction to 0.5% increase, low certainty). Risks of adverse events (all moderate, low, or very low certainty) were similar between placebo and TXA.
CONCLUSIONS: In patients with acute TBI, TXA probably has no effect on mortality or disability. TXA may decrease hematoma expansion on subsequent imaging; however, this outcome is likely of less importance to patients. The use of TXA probably does not increase the risk of adverse events.
参考来源
- Lawati KA, Sharif S, Maqbali SA, et al. Efficacy and safety of tranexamic acid in acute traumatic brain injury: a systematic review and meta-analysis of randomized-controlled trials. Intensive Care Med. 2020. PMID: 33079217. doi:10.1007/s00134-020-06279-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。